China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to launch Bentrio nasal spray in Hong Kong and Macau. Under the agreement, DKSH HK will provide full-agency services, including key account management, marketing promotions, supply chain, and distribution for Bentrio Nasal Spray sales operations in the region. Financial details of the partnership were not disclosed.
Product Profile and Market Expansion
Bentrio is an OTC drug-free nasal spray designed to protect against airborne disease-causing agents, including allergens and viruses. Nuance Pharma entered into an exclusive licensing and distribution agreement with Altamira Therapeutics in March for Bentrio, covering mainland China, Hong Kong, Macau, and South Korea. The product is already marketed in several countries throughout Europe and Asia to help protect against allergic rhinitis and has received 510(k) clearance from the US FDA for the treatment of allergic rhinitis (hay fever). It is classified as a Class I medical device in the UK.
Clinical and Market Presence
Bentrio’s efficacy and protective effects have been demonstrated through multiple clinical and in vitro studies. In Europe, including Germany, the product is marketed for helping to prevent the onset and alleviate allergic symptoms caused by airborne allergens such as pollen, house dust mites, or animal dander. In other markets like Singapore, Bentrio is marketed for protection against airborne viruses and allergens. The partnership with DKSH HK aims to expand Bentrio’s presence in Hong Kong and Macau, leveraging DKSH’s comprehensive service capabilities.-Fineline Info & Tech
